Dr. Sullivan on Treatment Options in BRAF-Mutant Melanoma

Video

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Ryan Sullivan, MD, medical oncologist, attending physician, Division of Hematology/Oncology, Massachusetts General Hospital, discusses treatment options in BRAF-mutant melanoma.

Patients with melanoma who harbor a BRAF mutation are eligible to receive combination BRAF/MEK inhibitor therapy, ipilimumab (Yervoy) in combination with nivolumab (Opdivo), or single-agent checkpoint inhibitor therapy with nivolumab or pembrolizumab (Keytruda) in the frontline setting, says Sullivan. However, BRAF-targeted therapy is not appropriate for patients without BRAF mutations.

Single-agent nivolumab and pembrolizumab, as well as the BRAF/MEK inhibitor combination of dabrafenib (Tafinlar) and trametinib (Mekinist) are approved for use in the adjuvant setting for patients with BRAF-mutant disease, Sullivan explains. Although the tendency is to offer immunotherapy up front to patients with metastatic melanoma, it may be preferable to offer patients with BRAF mutations BRAF-targeted therapy rather than checkpoint inhibitors in the adjuvant space, concludes Sullivan.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,